STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more

US Health and Human Services Secretary Robert F. Kennedy Jr. has announced initiatives to reduce the prescription of selective serotonin reuptake inhibitors, a class of antidepressants. Johnson & Johnson is advancing a therapy for inflammatory bowel disease into late-stage testing despite initial results not showing statistically meaningful improvement. The initiatives aim to help patients get off medications and consider non-pharmaceutical interventions.